Emergent BioSolutions
Emergent BioSolutions is dedicated to developing, manufacturing, and delivering medical countermeasures that address public health threats. With a mission to protect and enhance life, the company focuses on innovative vaccines and therapeutics to combat critical health challenges, including the ongoing opioid crisis.
Emergent BioSolutions
What We Do
Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.
Medical Countermeasures
Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.
Commercial Products
Emergent offers commercialized products that address endemic public health threats such as the opioid epidemic.
NARCAN® Nasal Spray is designed to rapidly reverse the effects of a life-threatening opioid overdose emergency in minutes.
ACAM2000®
Smallpox and Mpox (Vaccinia) Vaccine, Live.
BioThrax®
Anthrax Vaccine Adsorbed, used for the prevention of anthrax disease.
Services
Battlefield Resuscitation
Psychological and Cognitive Health and Performance
Key People
News & Updates
Emergent BioSolutions announced that brincidofovir will be included in a clinical trial conducted by PANTHER, evaluating its safety and efficacy in treating mpox virus.
Emergent BioSolutions reported financial results for the third quarter ended September 30, 2024.
Emergent BioSolutions announced the appointment of Simon Lowry, M.D., as chief medical officer, effective November 18.